These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7908399)

  • 41. [Effects and side effects of depot neuroleptics as perceived by patients].
    Trenckmann U
    Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
    Cohen S; Khan A; Zheng Y; Chiles J
    Acta Psychiatr Scand; 1991 Mar; 83(3):234-7. PubMed ID: 1674398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The concept of supersensitivity psychosis.
    Kirkpatrick B; Alphs L; Buchanan RW
    J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics.
    Prosser ES; Csernansky JG; Kaplan J; Thiemann S; Becker TJ; Hollister LE
    J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
    Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
    Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of novel antipsychotic drugs.
    Raleigh F
    Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuroleptics and nicotine].
    Erdmann R
    Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current data on neurologic sequelae caused by neuroleptics].
    Krebs MO
    Encephale; 1995 Jun; 21 Spec No 3():49-52. PubMed ID: 7628342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
    Briken P; Nika E; Krausz M; Naber D
    Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment.
    Kaneko M; Honda K; Kanno T; Horikoshi R; Manome T; Watanabe A; Kumashiro H
    Neuropsychobiology; 1992; 25(3):126-9. PubMed ID: 1357582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Atypical neuroleptics--the future of schizophrenia treatment?].
    Ebert D
    Fortschr Med; 1998 Jan; 116(3):22-8. PubMed ID: 9522541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antipsychotics of different clinical/pharmacological groups in treatment of negative disorders in schizophrenia].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(9):116-23. PubMed ID: 25473665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neuroleptics and sexual dysfunction in man. Neuroendocrine aspects].
    Martin-Du Pan R
    Schweiz Arch Neurol Neurochir Psychiatr; 1978; 122(2):285-313. PubMed ID: 29337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of neuroleptics in an integrated treatment program for chronic schizophrenics.
    Gottfries I; Rüdeberg K
    Acta Psychiatr Scand Suppl; 1981; 291():44-55. PubMed ID: 6113734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Psychological effects of previous treatment experiences with neuroleptics].
    Bossert S; Dose M; Emrich HM; Garcia D; Junker M; Raptis K; Weber MM
    Nervenarzt; 1990 May; 61(5):301-5. PubMed ID: 1972785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Atypical neuroleptics--a heterogenous group. Valuable option in acute psychoses].
    MMW Fortschr Med; 2002 May; Suppl 2():85. PubMed ID: 12070863
    [No Abstract]   [Full Text] [Related]  

  • 60. [Effect of neuroleptics on depressive symptoms].
    Tabeze JP
    Encephale; 1998 Jul; 24 Spec No 1():38-41. PubMed ID: 9809254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.